MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

24.09 2.73

Buy Sell

Overview

Share price change

24h

Current

Min

23.92

Max

24.23

Key metrics
By Trading Economics
Income	-14M -50M
Sales	12M 128M
Profit margin	-39.506
Employees	1,784
EBITDA	-17M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+42.41% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	200M 2.4B
Previous open	21.36
Previous close	24.09

News Sentiment

By Acuity

43%

57%

124 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 kwi 2026, 23:48 UTC

Major News Events

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 kwi 2026, 23:36 UTC

Major News Events

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 kwi 2026, 22:47 UTC

Major News Events

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

20 kwi 2026, 00:00 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

20 kwi 2026, 00:00 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 kwi 2026, 23:49 UTC

Market Talk

Major News Events

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 kwi 2026, 23:38 UTC

Major News Events

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 kwi 2026, 23:12 UTC

Major News Events

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 kwi 2026, 23:10 UTC

Major News Events

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 kwi 2026, 23:09 UTC

Major News Events

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 kwi 2026, 23:08 UTC

Major News Events

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 kwi 2026, 01:00 UTC

Major News Events

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

42.41% upside

12 Months Forecast

Average 34.45 USD 42.41%

High 47 USD

Low 21.8 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

124 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.